Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Tracleer Tackling Pulmonary Fibrosis

Endothelin Blocker Close to Market

    This is a preview of subscription content, log in to check access.

    Table I

    Notes

    1. 1.

      Bosentan Use in Interstitial Lung Diseases.

    2. 2.

      International Study of Survival Outcomes in Idiopathic Pulmonary Fibrosis With Interferon Gamma Early Intervention.

    References

    1. 1.

      European Biotechnology. Actelion. Tracleer clinician call review. New York: Lehman Brothers Equity Research 2005

    2. 2.

      European Biotechnology. Actelion. No change to numbers following R&D day. New York: Lehman Brothers Equity Research 2005

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Tracleer Tackling Pulmonary Fibrosis. Pharmaceutical & Diagnostic Innovation 3, 8–12 (2005). https://doi.org/10.1007/BF03256992

    Download citation

    Keywords

    • Pulmonary Arterial Hypertension
    • Idiopathic Pulmonary Fibrosis
    • Pulmonary Fibrosis
    • Actimmune
    • Tracleer